Zaoral M, Kolc J and Šorm F: Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-γ-aminobutyrine-vasopressin, 1-deamino-8-D-lysine-vasopressin, and 1-deamino-8-D-arginine-vasopressin. Collect Czech Chem Commun. 32:1250–1257. 1967.

Robinson AG: DDAVP in the treatment of central diabetes insipidus. N Engl J Med. 294:507–511. 1976.PubMed/NCBI View Article : Google Scholar

Desmopressin | Drugs | BNF content published by NICE. https://bnf.nice.org.uk/drugs/desmopressin/. Accessed March 22, 2023.

Cash JD: DDAVP and factor VIII: A tale from Edinburgh. J Thromb Haemost. 1:619–621. 2003.PubMed/NCBI View Article : Google Scholar

Mannucci PM, Ruggeri ZM, Pareti FI and Capitanio A: 1-Deamino-8-d-arginine vasopressin: A new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet. 1:869–872. 1977.PubMed/NCBI View Article : Google Scholar

Mannucci PM: Use of desmopressin in the treatment of hemophilia A: Towards a golden jubilee. Haematologica. 103:379–381. 2018.PubMed/NCBI View Article : Google Scholar

Robson WLM, Leung AKC and Norgaard JP: The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis. J Urol. 178:24–30. 2007.PubMed/NCBI View Article : Google Scholar

Juul KV, Malmberg A, van der Meulen E, Walle JV and Nørgaard JP: Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for Nocturia. BJU Int. 119:776–784. 2017.PubMed/NCBI View Article : Google Scholar

De Bruyne P, De Guchtenaere A, Van Herzeele C, Raes A, Dehoorne J, Hoebeke P, Van Laecke E and Walle JV: Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis. Eur J Pediatr. 173:223–228. 2014.PubMed/NCBI View Article : Google Scholar

Dossche L, Michelet R, De Bruyne P, Van Herzeele C, Gasthuys E, Rittig S, Vermeulen A and Walle JV: Desmopressin oral lyophilisate in young children: New insights in pharmacokinetics and pharmacodynamics. Arch Dis Child. 106:597–602. 2021.PubMed/NCBI View Article : Google Scholar

De Guchtenaere A, Van Herzeele C, Raes A, Dehoorne J, Hoebeke P, Van Laecke E and Walle JV: Oral lyophylizate formulation of desmopressin: Superior pharmacodynamics compared to tablet due to low food interaction. J Urol. 185:2308–2313. 2011.PubMed/NCBI View Article : Google Scholar

Fjellestad-Paulsen A, Höglund P, Lundin S and Paulsen O: Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol (Oxf). 38:177–182. 1993.PubMed/NCBI View Article : Google Scholar

Rembratt A, Graugaard-Jensen C, Senderovitz T, Norgaard JP and Djurhuus JC: Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur J Clin Pharmacol. 60:397–402. 2004.PubMed/NCBI View Article : Google Scholar

Mohinani A, Patel S, Tan V, Kartika T, Olson S, DeLoughery TG and Shatzel J: Desmopressin as a hemostatic and blood sparing agent in bleeding disorders. Eur J Haematol. 110:470–479. 2023.PubMed/NCBI View Article : Google Scholar

Mannucci PM: Desmopressin (DDAVP) in the treatment of bleeding disorders, Revised edition, 2012.

Electronic Medicines Compendium: DDAVP/Desmopressin Injection-Summary of Product Characteristics (SmPC)-(emc). https://www.medicines.org.uk/emc/product/5447/smpc#gref. Last accessed July 12, 2023.

Electronic medicines compendium: Octim Nasal Spray-Summary of Product Characteristics (SmPC) - (emc). https://www.medicines.org.uk/emc/product/89/smpc#gref. Last accessed 12 July, 2023.

Akin M: Response to low-dose desmopressin by a subcutaneous route in children with type 1 von Willebrand disease. Hematology. 18:115–118. 2013.PubMed/NCBI View Article : Google Scholar

Furqan F, Sham R and Kouides P: Efficacy and safety of half-dose desmopressin for bleeding prophylaxis in bleeding disorder patients undergoing predominantly low to moderate risk invasive procedures. Am J Hematol. 95:E285–E287. 2020.PubMed/NCBI View Article : Google Scholar

Preijers T, Schütte LM, Kruip MJHA, Cnossen MH, Leebeek FWG, van Hest RM and Mathôt RAA: Strategies for individualized dosing of clotting factor concentrates and desmopressin in hemophilia A and B. Ther Drug Monit. 41:192–212. 2019.PubMed/NCBI View Article : Google Scholar

Preijers T, Schütte LM, Kruip MJHA, Cnossen MH, Leebeek FWG, van Hest RM and Mathôt RAA: Population pharmacokinetics of clotting factor concentrates and desmopressin in hemophilia. Clin Pharmacokinet. 60:1–16. 2021.PubMed/NCBI View Article : Google Scholar

Atiq F, Heijdra J, Snijders F, Boender J, Kempers E, van Heerde WL, Maas DPMSM, Krouwel S, Schoormans SC, de Meris J, et al: Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease. Blood Adv. 6:5317–5326. 2022.PubMed/NCBI View Article : Google Scholar

Trigg DE, Stergiotou I, Peitsidis P and Kadir RA: A systematic review: The use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia. 18:25–33. 2012.PubMed/NCBI View Article : Google Scholar

Kouides PA, Byams VR, Philipp CS, Stein SF, Heit JA, Lukes AS, Skerrette NI, Dowling NF, Evatt BL, Miller CH, et al: Multisite management study of menorrhagia with abnormal laboratory haemostasis: A prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol. 145:212–220. 2009.PubMed/NCBI View Article : Google Scholar

Saccullo G and Makris M: Prophylaxis in von Willebrand disease: Coming of age? Semin Thromb Hemost. 42:498–506. 2016.PubMed/NCBI View Article : Google Scholar

Andersen LK, Hvas AM and Hvas CL: Effect of desmopressin on platelet dysfunction during antiplatelet therapy: A systematic review. Neurocrit Care. 34:1026–1046. 2021.PubMed/NCBI View Article : Google Scholar

Benvenuto L, Qayum S, Kim H, Robbins H, Shah L, Dimango A, Magda G, Grewal H, Lemaitre P, Stanifer BP, et al: Lung transplantation for pulmonary fibrosis associated with hermansky-pudlak syndrome. A single-center experience. Transplant Direct. 8(e1303)2022.PubMed/NCBI View Article : Google Scholar

Merideth MA, Introne WJ, Wang JA, O'Brien KJ, Huizing M and Gochuico BR: Genetic variants associated with Hermansky-Pudlak syndrome. Platelets. 31:544–547. 2020.PubMed/NCBI View Article : Google Scholar

MacDonald S, Wright A, Beuche F, Downes K, Besser M, Symington E, Kelly A and Thomas W: Characterization of a large cohort of patients with unclassified bleeding disorder clinical features, management of haemostatic challenges and use of global haemostatic assessment with proposed recommendations for diagnosis and treatment. Int J Lab Hematol. 42:116–125. 2020.PubMed/NCBI View Article : Google Scholar

Obaji S, Alikhan R, Rayment R, Carter P, Macartney N and Collins P: Unclassified bleeding disorders: Outcome of haemostatic challenges following tranexamic acid and/or desmopressin. Haemophilia. 22:285–291. 2016.PubMed/NCBI View Article : Google Scholar

Czer LS, Bateman TM, Gray RJ, Raymond M, Stewart ME, Lee S, Goldfinger D, Chaux A and Matloff JM: Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: Reduction in blood product usage with desmopressin. J Am Coll Cardiol. 9:1139–1147. 1987.PubMed/NCBI View Article : Google Scholar

Wademan BH and Galvin SD: Desmopressin for reducing postoperative blood loss and transfusion requirements following cardiac surgery in adults. Interact Cardiovasc Thorac Surg. 18:360–370. 2014.PubMed/NCBI View Article : Google Scholar

Radhakrishnan S, Chanchlani R, Connolly B and Langlois V: Pre-procedure desmopressin acetate to reduce bleeding in renal failure: Does it really work? Nephron Clin Pract. 128:45–48. 2014.PubMed/NCBI View Article : Google Scholar

Athavale A, Kulkarni H, Arslan CD and Hart P: Desmopressin and bleeding risk after percutaneous kidney biopsy. BMC Nephrol. 20(413)2019.PubMed/NCBI View Article : Google Scholar

Akbarpour M, Jalali MM, Akbari M, Haddadi S and Fani G: Effect of desmopressin on bleeding during endoscopic sinus surgery: A randomized clinical trial. Laryngoscope Investig Otolaryngol. 7:920–927. 2022.PubMed/NCBI View Article : Google Scholar

Haddady-Abianeh S, Rajabpour AA, Sanatkarfar M, Farahvash MR, Khorasani G and Molaei H: The hemostatic effect of desmopressin on bleeding as a nasal spray in open septorhinoplasty. Aesthetic Plast Surg. 43:1603–1606. 2019.PubMed/NCBI View Article : Google Scholar

Jahanshahi J, Tayebi E, Hashemian F, Bakhshaei MH, Ahmadi MS and Rabiei MA: Effect of local desmopressin administration on intraoperative blood loss and quality of the surgical field during functional endoscopic sinus surgery in patients with chronic rhinosinusitis: A triple-blinded clinical trial. Eur Arch Otorhinolaryngol. 276:1995–1999. 2019.PubMed/NCBI View Article : Google Scholar

Safaeian R, Hassani V, Ghandi A and Mohseni M: Desmopressin nasal spray reduces blood loss and improves the quality of the surgical field during functional endoscopic sinus surgery. J Anaesthesiol Clin Pharmacol. 37:261–265. 2021.PubMed/NCBI View Article : Google Scholar

Shao H, Kuang LT, Hou WJ and Zhang T: Effect of desmopressin administration on intraoperative blood loss and quality of the surgical field during functional endoscopic sinus surgery: A randomized, clinical trial. BMC Anesthesiol. 15(53)2015.PubMed/NCBI View Article : Google Scholar

Frontera JA, Lewin JJ III, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, Del Zoppo GJ, Kumar M, Peerschke EI, Stiefel MF, et al: Guideline for reversal of antithrombotics in intracranial hemorrhage: Executive summary. A statement for healthcare professionals from the neurocritical care society and the society of critical care medicine. Crit Care Med. 44:2251–2257. 2016.PubMed/NCBI View Article : Google Scholar

Mengel A, Stefanou MI, Hadaschik KA, Wolf M, Stadler V, Poli K, Lindig T, Ernemann U, Grimm F, Tatagiba M, et al: Early administration of Desmopressin and platelet transfusion for reducing hematoma expansion in patients with acute antiplatelet therapy associated Intracerebral Hemorrhage. Crit Care Med. 48:1009–1017. 2020.PubMed/NCBI View Article : Google Scholar

Loggini A, El Ammar F, Darzi AJ, Mansour A, Kramer CL, Goldenberg FD and Lazaridis C: Effect of desmopressin on hematoma expansion in antiplatelet-associated intracerebral hemorrhage: A systematic review and meta-analysis. J Clin Neurosci. 86:116–121. 2021.PubMed/NCBI View Article : Google Scholar

Bultitude M and Rees J: Management of renal colic. BMJ. 345(e5499)2012.PubMed/NCBI View Article : Google Scholar

Golzari SE, Soleimanpour H, Rahmani F, Mehr NZ, Safari S, Heshmat Y and Bakhtavar HE: Therapeutic approaches for renal colic in the emergency department: A review article. Anesth Pain Med. 4(e16222)2014.PubMed/NCBI View Article : Google Scholar

Kapila V, Kapila AK, Tailly T, Rappe B, Juul KV and Everaert K: The analgesic action of desmopressin in renal colic. Acta Clin Belg. 72:179–185. 2017.PubMed/NCBI View Article : Google Scholar

Patti L and Leslie SW: Acute renal colic. StatPearls Publishing, 2022.

Juul KV, Schroeder MK, Rittig S and Nørgaard JP: Desmopressin as an adjuvant to opioids or NSAIDs in treatment of renal colic: A nationwide register-based study. Pharmacoepidemiol Drug Saf. 24:1155–1160. 2015.PubMed/NCBI View Article : Google Scholar

Amer T, Osman B, Johnstone A, Mariappan M, Gupta A, Brattis N, Jones G, Somani BK, Keeley FX Jr and Aboumarzouk OM: Medical expulsive therapy for ureteric stones: Analysing the evidence from systematic reviews and meta-analysis of powered double-blinded randomised controlled trials. Arab J Urol. 15:83–93. 2017.PubMed/NCBI View Article : Google Scholar

Campschroer T, Zhu X, Vernooij RW and Lock MT: Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev. 5(CD08509)2018.PubMed/NCBI View Article : Google Scholar

Lim I, Sellers DJ and Chess-Williams R: Current and emerging pharmacological targets for medical expulsive therapy. Basic Clin Pharmacol Toxicol. 130 (Suppl 1):S16–S22. 2022.PubMed/NCBI View Article : Google Scholar

European Association of Urology (EAU): EAU Guidelines on Urolithiasis. EAU, Arnhem, 2024. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urolithiasis-2024.pdf.

Jalili M, Shirani F, Entezari P, Hedayatshodeh M, Baigi V and Mirfazaelian H: Desmopressin/indomethacin combination efficacy and safety in renal colic pain management: A randomized placebo controlled trial. Am J Emerg Med. 37:1009–1012. 2019.PubMed/NCBI View Article : Google Scholar

Kimoto Y and Constantinou CE: Effects of [1-desamino-8-D-arginine]vasopressin and papaverine on rabbit renal pelvis. Eur J Pharmacol. 175:359–362. 1990.PubMed/NCBI View Article : Google Scholar

el-Sherif AE, Salem M, Yahia H, al-Sharkawy WA and al-Sayrafi M: Treatment of renal colic by desmopressin intranasal spray and diclofenac sodium. J Urol. 153:1395–1398. 1995.PubMed/NCBI

Hazhir S, Badr YAA and Darabi JN: Comparison of intranasal desmopressin and intramuscular tramadol versus pethidine in patients with renal colic. Urol J. 7:148–151. 2010.PubMed/NCBI View Article : Google Scholar

Kheirollahi AR, Tehrani M and Bashashati M: A comparison of the effect of intranasal desmopressin and intramuscular hyoscine N-butyl bromide combination with intramuscular hyoscine N-butyl bromide alone in acute renal colic. J Res Med Sci. 15:214–218. 2010.PubMed/NCBI

Roshani A, Falahatkar S, Khosropanah I, Roshan ZA, Zarkami T, Palizkar M, Emadi SA, Akbarpour M and Khaki N: Assessment of clinical efficacy of intranasal desmopressin spray and diclofenac sodium suppository in treatment of renal colic versus diclofenac sodium alone. Urology. 75:540–542. 2010.PubMed/NCBI View Article : Google Scholar

Masoumi K, Darian AS, Forouzan A, Barzegari H, Rahim F, Feli M, Sheidaii MF and Porozan S: The efficacy of intranasal desmopressin as an adjuvant in the acute renal colic pain management. Pain Res Treat. 2014(320327)2014.PubMed/NCBI View Article : Google Scholar

Shirvani MK, Mahboub MD, Ghazi M and Delijani A: A comparison of the effects of morphine and sublingual desmopressin combination therapy with morphine alone in treatment of renal colic: A controlled clinical trial. Urol J. 12:2001–2004. 2015.PubMed/NCBI

Shirazi M, Salehipour M, Afrasiabi MA and Aminsharifi A: Analgesic effects and safety of desmopressin, tramadol and indomethacin in patients with acute renal colic; A randomized clinical trial. Bull Emerg Trauma. 3:41–45. 2015.PubMed/NCBI

Dolatabadi AA, Memary E, Kariman H, Gigloo KN and Baratloo A: Intranasal desmopressin compared with intravenous ketorolac for pain management of patients with renal colic referring to the emergency department: A randomized clinical trial. Anesth Pain Med. 7(e43595)2017.PubMed/NCBI View Article : Google Scholar

Ghafouri HB, Abazarian N, Yasinzadeh M and Modirian E: Intravenous paracetamol vs intranasal desmopressin for renal colic in the emergency department: A randomized clinical trial. Pain Med. 21:3437–3442. 2020.PubMed/NCBI View Article : Google Scholar

Pricop C, Branisteanu DD, Orsolya M, Puia D, Matei A and Checherita IA: Sublingual desmopressin is efficient and safe in the therapy of lithiasic renal colic. Int Urol Nephrol. 48:183–189. 2016.PubMed/NCBI View Article : Google Scholar

Kumar S, Behera NC, Sarkar D, Prasad S, Mandal AK and Singh SK: A comparative assessment of the clinical efficacy of intranasal desmopressin spray and diclofenac in the treatment of renal colic. Urol Res. 39:397–400. 2011.PubMed/NCBI View Article : Google Scholar

Lopes T, Dias JS, Marcelino J, Varela J, Ribeiro S and Dias J: An assessment of the clinical efficacy of intranasal desmopressin spray in the treatment of renal colic. BJU Int. 87:322–325. 2001.PubMed/NCBI View Article : Google Scholar

Jalili M, Entezari P, Doosti-Irani A, Masoomi R and Mirfazaelian H: Desmopressin effectiveness in renal colic pain management: Systematic review and meta-analysis. Am J Emerg Med. 34:1535–1541. 2016.PubMed/NCBI View Article : Google Scholar

Seghatoleslami G, Jahromi MS, Farzaneh R, Rahsepar S, Malekshoar M, Vatankhah M, Akhavan R, Abbasi B, Akhavan H, Abiri S, et al: Alternative medical interventions versus conventional treatment of renal colic: An updated systematic review and network meta-analysis. Urol J. 19:412–419. 2022.PubMed/NCBI View Article : Google Scholar

Kreek MJ, Zhou Y and Levran O: Functions of arginine vasopressin and its receptors: Importance of human molecular genetics studies in bidirectional translational research. Biol Psychiatry. 70:502–503. 2011.PubMed/NCBI View Article : Google Scholar

Albers HE: The regulation of social recognition, social communication and aggression: Vasopressin in the social behavior neural network. Horm Behav. 61:283–292. 2012.PubMed/NCBI View Article : Google Scholar

Winter J and Jurek B: The interplay between oxytocin and the CRF system: Regulation of the stress response. Cell Tissue Res. 375:85–91. 2019.PubMed/NCBI View Article : Google Scholar

Marsh N, Marsh AA, Lee MR and Hurlemann R: Oxytocin and the neurobiology of prosocial behavior. Neuroscientist. 27:604–619. 2021.PubMed/NCBI View Article : Google Scholar

Müller D, Florkowski H, Chavez-Kattau K, Carlsson G and Eggert P: The effect of desmopressin on short-term memory in children with primary nocturnal enuresis. J Urol. 166:2432–2434. 2001.PubMed/NCBI

Schulz-Juergensen S, Rieger M, Schaefer J, Neusuess A and Eggert P: Effect of 1-desamino-8-D-arginine vasopressin on prepulse inhibition of startle supports a central etiology of primary monosymptomatic enuresis. J Pediatr. 151:571–574. 2007.PubMed/NCBI View Article : Google Scholar

Laczi F, Valkusz Z, Lászlo FA, Wagner A, Járdánházy T, Szász A, Szilárd J and Telegdy G: Effects of lysine-vasopressin and 1-deamino-8-D-arginine-vasopressin on memory in healthy individuals and diabetes insipidus patients. Psychoneuroendocrinology. 7:185–193. 1982.PubMed/NCBI View Article : Google Scholar

EMBL-EBI: Expression Atlas-gene expression across species and biological conditions. https://www.ebi.ac.uk/gxa/home. Last accessed 12 July, 2023.

Charles R, Sakurai T, Takahashi N, Elder GA, Sosa MA, Young LJ and Buxbaum JD: Introduction of the human AVPR1A gene substantially alters brain receptor expression patterns and enhances aspects of social behavior in transgenic mice. Dis Model Mech. 7:1013–1022. 2014.PubMed/NCBI View Article : Google Scholar

Ebstein RP, Knafo A, Mankuta D, Chew SH and Lai PS: The contributions of oxytocin and vasopressin pathway genes to human behavior. Horm Behav. 61:359–379. 2012.PubMed/NCBI View Article : Google Scholar

GTEX Consortium. Ardlie KG, Deluca DS, Segrè AV, Sullivan TJ, Young T, Gelfand ET, Trowbridge C, Maller JB, Tukiainen T, et al: The genotype-tissue expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science. 348:648–660. 2015.PubMed/NCBI View Article : Google Scholar

Vargas KJ, Sarmiento JM, Ehrenfeld P, Añazco CC, Villanueva CI, Carmona PL, Brenet M, Navarro J, Müller-Esterl W and González CB: Postnatal expression of V2 vasopressin receptor splice variants in the rat cerebellum. Differentiation. 77:377–385. 2009.PubMed/NCBI View Article : Google Scholar

Kato Y, Igarashi N, Hirasawa A, Tsujimoto G and Kobayashi M: Distribution and developmental changes in vasopressin V2 receptor mRNA in rat brain. Differentiation. 59:163–169. 1995.PubMed/NCBI View Article : Google Scholar

Schmahmann JD: Emotional disorders and the cerebellum: Neurobiological substrates, neuropsychiatry, and therapeutic implications. Handb Clin Neurol. 183:109–154. 2021.PubMed/NCBI View Article : Google Scholar

Tomlinson SP, Davis NJ, Morgan HM and Bracewell RM: Cerebellar contributions to verbal working memory. Cerebellum. 13:354–361. 2014.PubMed/NCBI View Article : Google Scholar

Sakai Y, Horiba N, Tozawa F, Sakai K, Kuwayama A, Demura H and Suda T: Desmopressin stimulation test for diagnosis of ACTH-dependent Cushing's syndrome. Endocr J. 44:687–695. 1997.PubMed/NCBI View Article : Google Scholar

Vassiliadi DA and Tsagarakis S: Diagnosis of Endocrine Disease: The role of the desmopressin test in the diagnosis and follow-up of Cushing's syndrome. Eur J Endocrinol. 178:R201–R214. 2018.PubMed/NCBI View Article : Google Scholar

Jonat S, Santer R, Schneppenheim R, Obser T and Eggert P: Effect of DDAVP on nocturnal enuresis in a patient with nephrogenic diabetes insipidus. Arch Dis Child. 81:57–59. 1999.PubMed/NCBI View Article : Google Scholar

Robben JH, Sze M, Knoers NV, Eggert P, Deen P and Müller D: Relief of nocturnal enuresis by desmopressin is kidney and vasopressin type 2 receptor independent. J Am Soc Nephrol. 18:1534–1539. 2007.PubMed/NCBI View Article : Google Scholar

Stegner H, Artman HG, Leake RD and Fisher DA: Does DDAVP (1-desamino-8-D-arginine-vasopressin) cross the blood-CSF barrier? Neuroendocrinology. 37:262–265. 1983.PubMed/NCBI View Article : Google Scholar

Sørensen PS, Vilhardt H, Gjerris F and Warberg J: Impermeability of the blood-cerebrospinal fluid barrier to 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with acquired, communicating hydrocephalus. Eur J Clin Invest. 14:435–439. 1984.PubMed/NCBI View Article : Google Scholar

Ferring Pharmaceuticals: DDAVP Tablets 0.2mg SmPC, 2012.

Banks WA, Kastin AJ, Horvath A and Michals EA: Carrier-mediated transport of vasopressin across the blood-brain barrier of the mouse. J Neurosci Res. 18:326–332. 1987.PubMed/NCBI View Article : Google Scholar

Su Y, Sun B, Gao X, Dong X, Fu L, Zhang Y, Li Z, Wang Y, Jiang H and Han B: Intranasal delivery of targeted nanoparticles loaded with miR-132 to brain for the treatment of neurodegenerative diseases. Front Pharmacol. 11(1165)2020.PubMed/NCBI View Article : Google Scholar

Lochhead JJ, Kellohen KL, Ronaldson PT and Davis TP: Distribution of insulin in trigeminal nerve and brain after intranasal administration. Sci Rep. 9(2621)2019.PubMed/NCBI View Article : Google Scholar

Maeng J and Lee K: Systemic and brain delivery of antidiabetic peptides through nasal administration using cell-penetrating peptides. Front Pharmacol. 13(1068495)2022.PubMed/NCBI View Article : Google Scholar

Hallschmid M: Intranasal insulin for Alzheimer's disease. CNS Drugs. 35:21–37. 2021.PubMed/NCBI View Article : Google Scholar

Mutsuga N, Shahar T, Verbalis JG, Xiang CC, Brownstein MJ and Gainer H: Regulation of gene expression in magnocellular neurons in rat supraoptic nucleus during sustained hypoosmolality. Endocrinology. 146:1254–1267. 2005.PubMed/NCBI View Article : Google Scholar

Landgraf R, Hess J and Hartmann E: Effect of oxytocin on regional 3H-orotic acid uptake in rat brain. Endokrinologie. 70:45–52. 1977.PubMed/NCBI(In German).

Landgraf R, Hess J and Ermisch A: The influence of vasopressin on the regional uptake of [3H] orotic acid by rat brain. Acta Biol Med Ger. 37:655–658. 1978.PubMed/NCBI

Burbach JP, Kovács GL, de Wied D, van Nispen JW and Greven HM: A major metabolite of arginine vasopressin in the brain is a highly potent neuropeptide. Science. 221:1310–1312. 1983.PubMed/NCBI View Article : Google Scholar

Burbach JP, Bohus B, Kovács GL, Van Nispen JW, Greven HM and De Wied D: Oxytocin is a precursor of potent behaviourally active neuropeptides. Eur J Pharmacol. 94:125–131. 1983.PubMed/NCBI View Article : Google Scholar

van Bree JB, de Boer AG, Verhoef JC, Danhof M and Breimer DD: Transport of vasopressin fragments across the blood-brain barrier: In vitro studies using monolayer cultures of bovine brain endothelial cells. J Pharmacol Exp Ther. 249:901–905. 1989.PubMed/NCBI

Lee MR and Jayant RD: Penetration of the blood-brain-barrier by peripheral neuropeptides: New approaches to enhancing transport and endogenous expression. Cell Tissue Res. 375:287–293. 2019.PubMed/NCBI View Article : Google Scholar

Lal S, Nair NP, Isaac I, Thavundayil J and Guyda H: Effect of some peptides on dopaminergic function in man. J Neural Transm Suppl. 29:173–181. 1990.PubMed/NCBI View Article : Google Scholar

Brambilla F, Aguglia E, Massironi R, Maggioni M, Grillo W, Castiglioni R, Catalano M and Drago F: Neuropeptide therapies in chronic schizophrenia: TRH and vasopressin administration. Neuropsychobiology. 15:114–121. 1986.PubMed/NCBI View Article : Google Scholar

Brambilla F, Bondiolotti GP, Maggioni M, Sciascia A, Grillo W, Sanna F, Latina A and Picotti GB: Vasopressin (DDAVP) therapy in chronic schizophrenia: Effects on negative symptoms and memory. Neuropsychobiology. 20:113–119. 1989.PubMed/NCBI View Article : Google Scholar

Pifano M, Garona J, Capobianco CS, Gonzalez N, Alonso DF and Ripoll GV: Peptide agonists of vasopressin V2 receptor reduce expression of neuroendocrine markers and tumor growth in human lung and prostate tumor cells. Front Oncol. 7(11)2017.PubMed/NCBI View Article : Google Scholar

Keegan BP, Akerman BL, Péqueux C and North WG: Provasopressin expression by breast cancer cells: Implications for growth and novel treatment strategies. Breast Cancer Res Treat. 95:265–277. 2006.PubMed/NCBI View Article : Google Scholar

Sobol NT, Solernó LM, Beltrán B, Vásquez L, Ripoll GV, Garona J and Alonso DF: Anticancer activity of repurposed hemostatic agent desmopressin on AVPR2-expressing human osteosarcoma. Exp Ther Med. 21(566)2021.PubMed/NCBI View Article : Google Scholar

Bass R, Roberto D, Wang DZ, Cantu FP, Mohamadi RM, Kelley SO, Klotz L and Venkateswaran V: Combining desmopressin and docetaxel for the treatment of castration-resistant prostate cancer in an orthotopic model. Anticancer Res. 39:113–118. 2019.PubMed/NCBI View Article : Google Scholar

Weinberg RS, Grecco MO, Ferro GS, Seigelshifer DJ, Perroni NV, Terrier FJ, Sánchez-Luceros A, Maronna E, Sánchez-Marull R, Frahm I, et al: A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients. Springerplus. 4(428)2015.PubMed/NCBI View Article : Google Scholar

Iseas S, Roca EL, O'Connor JM, Eleta M, Sanchez-Luceros A, Di Leo D, Tinelli M, Fara ML, Spitzer E, Demarco IA, et al: Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: Results of a phase I/II trial. Invest New Drugs. 38:1580–1587. 2020.PubMed/NCBI View Article : Google Scholar

Hermo GA, Torres P, Ripoll GV, Scursoni AM, Gomez DE, Alonso DF and Gobello C: Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: A pilot study. Vet J. 178:103–108. 2008.PubMed/NCBI View Article : Google Scholar

Ikeda Y, Zabbarova I, de Rijk M, Kanai A, Wolf-Johnston A, Weiss JP, Jackson E and Birder L: Effects of vasopressin receptor agonists on detrusor smooth muscle tone in young and aged bladders: Implications for nocturia treatment. Continence (Amst). 2022(100032)2022.PubMed/NCBI View Article : Google Scholar

Papatheodorou I, Moreno P, Manning J, Fuentes AM, George N, Fexova S, Fonseca NA, Füllgrabe A, Green M, Huang N, et al: Expression atlas update: From tissues to single cells. Nucl Acids Res. 48:D77–D83. 2020.PubMed/NCBI View Article : Google Scholar

Oiso Y, Robertson GL, Nørgaard JP and Juul KV: Clinical review: Treatment of neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab. 98:3958–3967. 2013.PubMed/NCBI View Article : Google Scholar

Altun G, Hemşinli D, Pulathan Z and Civelek A: Emergency coronary bypass surgery in patients under the influence of dualantiplatelet therapy: Effects of tranexamic acid and desmopressin acetate. Turk J Med Sci. 47:doi: 10.3906/sag-1612-140. 2017.PubMed/NCBI View Article : Google Scholar

Bignami E, Cattaneo M, Crescenzi G, Ranucci M, Guarracino F, Cariello C, Baldassarri R, Isgrò G, Baryshnikova E, Fano G, et al: Desmopressin after cardiac surgery in bleeding patients. A multicenter randomized trial. Acta Anaesthesiol Scand. 60:892–900. 2016.PubMed/NCBI View Article : Google Scholar

Jahangirifard A, Razavi MR, Ahmadi ZH and Forozeshfard M: Effect of desmopressin on the amount of bleeding and transfusion requirements in patients undergoing heart transplant surgery. Basic Clin Pharmacol Toxicol. 121:175–180. 2017.PubMed/NCBI View Article : Google Scholar

Jin L and Ji HW: Effect of desmopressin on platelet aggregation and blood loss in patients undergoing valvular heart surgery. Chin Med J. 128:644–647. 2015.PubMed/NCBI View Article : Google Scholar

Mirmansoori A, Farzi F, Sedighinejad A, Imantalab V, Mohammadzadeh A, Roushan ZA, Tehran SZ, Nemati M and Dehghan A: The effect of desmopressin on the amount of bleeding in patients undergoing coronary artery bypass graft surgery with a cardiopulmonary bypass pump after taking anti-platelet medicine. Anesth Pain Med. 6(e39226)2016.PubMed/NCBI View Article : Google Scholar

Cheong M, Lee TY, Lee J and Kim SB: No effect of desmopressin administration before kidney biopsy on the risk of major post-biopsy bleeding. Nefrologia (Engl Ed). 26:S0211–S6995. 2021.PubMed/NCBI View Article : Google Scholar : (In English, Spanish).

Leclerc S, Nadeau-Fredette AC, Elftouh N, Lafrance JP, Pichette V and Laurin LP: Use of desmopressin prior to kidney biopsy in patients with high bleeding risk. Kidney Int Rep. 5:1180–1187. 2020.PubMed/NCBI View Article : Google Scholar

Wang LC, Hu YF, Chen L, Xing R, Lin XF and Kou QY: Desmopressin acetate decreases blood loss in patients with massive hemorrhage undergoing gastrointestinal surgery. Turk J Gastroenterol. 31:474–481. 2020.PubMed/NCBI View Article : Google Scholar

Anderson LT, David R, Bonnet K and Dancis J: Passive avoidance learning in Lesch-Nyhan disease: Effect of 1-desamino-8-arginine-vasopressin. Life Sci. 24:905–910. 1979.PubMed/NCBI View Article : Google Scholar

Beckwith BE, Petros T, Kanaan-Beckwith S, Couk DI, Haug RJ and Ryan C: Vasopressin analog (DDAVP) facilitates concept learning in human males. Peptides. 3:627–630. 1982.PubMed/NCBI View Article : Google Scholar

Eisenberg J, Hamburger-Bar R and Belmaker RH: The effect of vasopressin treatment on learning in Down's syndrome. J Neural Transm. 60:143–147. 1984.PubMed/NCBI View Article : Google Scholar

Beckwith BE, Petros TV, Bergloff PJ and Staebler RJ: Vasopressin analogue (DDAVP) facilitates recall of narrative prose. Behav Neurosci. 101:429–432. 1987.PubMed/NCBI View Article : Google Scholar

Beckwith BE, Petros TV, Bergloff PJ, Swenson RR and Paulson R: Failure of posttrial administration of vasopressin analogue (DDAVP) to influence memory in healthy, young, male volunteers. Peptides. 16:1327–1328. 1995.PubMed/NCBI View Article : Google Scholar

Beckwith BE, Till RE, Reno CR and Poland RE: Dose-dependent effects of DDAVP on memory in healthy young adult males: A preliminary study. Peptides. 11:473–476. 1990.PubMed/NCBI View Article : Google Scholar

Eisenhofer G, Lambie DG and Robinson BJ: No improvement in ethanol-induced memory deficits after administration of a vasopressin analog. Life Sci. 37:2499–2505. 1985.PubMed/NCBI View Article : Google Scholar

Guard O, Marchal G, Graule A, Dumas R and D'Athis P: Effects of vasopressin and desmopressin on memory. A double-blind study in 40 healthy volunteers. Neuropsychobiology. 15:80–83. 1986.PubMed/NCBI View Article : Google Scholar

Jenkins JS, Mather HM and Coughlan AK: Effect of desmopressin on normal and impaired memory. J Neurol Neurosurg Psychiatry. 45:830–831. 1982.PubMed/NCBI View Article : Google Scholar

Millar K, Jeffcoate WJ and Walder CP: Vasopressin and memory: Improvement in normal short-term recall and reduction of alcohol-induced amnesia. Psychol Med. 17:335–341. 1987.PubMed/NCBI View Article : Google Scholar

Nebes RD, Reynolds CF III and Horn LC: The effect of vasopressin on memory in the healthy elderly. Psychiatry Res. 11:49–59. 1984.PubMed/NCBI View Article : Google Scholar

Till RE and Beckwith BE: Sentence memory affected by vasopressin analog (DDAVP) in cross-over experiment. Peptides. 6:397–402. 1985.PubMed/NCBI View Article : Google Scholar

Weingartner H, Gold P, Ballenger JC, Smallberg SA, Summers R, Rubinow DR, Post RM and Goodwin FK: Effects of vasopressin on human memory functions. Science. 211:601–603. 1981.PubMed/NCBI View Article : Google Scholar

Abdollahian E, Sargolzaee MR, Hajzade M, Mohebbi MD and Javanbakht A: Effects of desmopressin (DDAVP) on memory impairment following electroconvulsive therapy (ECT). Acta Neuropsychiatr. 16:130–137. 2004.PubMed/NCBI View Article : Google Scholar

Lerer B, Zabow T, Egnal N and Belmaker RH: Effect of vasopressin on memory following electroconvulsive therapy. Biol Psychiatry. 18:821–824. 1983.PubMed/NCBI

Beckwith BE, Couk DI and Till TS: Vasopressin analog influences the performance of males on a reaction time task. Peptides. 4:707–709. 1983.PubMed/NCBI View Article : Google Scholar

Jennings JR, Nebes RD and Reynolds CF III: Vasopressin peptide (DDAVP) may narrow the focus of attention in normal elderly. Psychiatry Res. 17:31–39. 1986.PubMed/NCBI View Article : Google Scholar

Tsikunov SG and Belokoskova SG: Psychophysiological analysis of the influence of vasopressin on speech in patients with post-stroke aphasias. Span J Psychol. 10:178–188. 2007.PubMed/NCBI View Article : Google Scholar

Gold PW, Weingartner H, Ballenger JC, Goodwin FK and Post RM: Effects of 1-desamo-8-D-arginine vasopressin on behaviour and cognition in primary affective disorder. Lancet. 2:992–994. 1979.PubMed/NCBI View Article : Google Scholar

Hosseini SMR, Farokhnia M, Rezaei F, Gougol A, Yekehtaz H, Iranpour N, Salehi B, Tabrizi M, Tajdini M, Ghaleiha A and Akhondzadeh S: Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial. Eur Neuropsychopharmacology. 24:846–855. 2014.PubMed/NCBI View Article : Google Scholar